Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Carboplatin + Paclitaxel + Pembrolizumab |
Indication/Tumor Type | cervical cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | cervical cancer | sensitive | Carboplatin + Paclitaxel + Pembrolizumab | FDA approved - On Companion Diagnostic | Actionable | In a Phase III trial (KEYNOTE-826) that supported FDA approval, first-line Keytruda (pembrolizumab) in combination with platinum-based chemotherapy (Platinol (cisplatin) or Paraplatin (carboplatin) plus Taxol (paclitaxel)), with or without Avastin (bevacizumab), improved progression-free survival (10.4 vs 8.1 mo, HR 0.62, p<0.001) compared to placebo in patients with CD274 (PD-L1)-positive (CPS>=1), persistent, recurrent or metastatic cervical cancer (PMID: 34534429; NCT03635567). | detail... 34534429 detail... |
PubMed Id | Reference Title | Details |
---|---|---|
Full reference... | ||
Keytruda (pembrolizumab) FDA Drug Label | Full reference... | |
(34534429) | Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. | Full reference... |